Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Urothelial Cancer × Midazolam × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urothelial Cancer 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Biphenotypic, Acute 1 Leukemia 1 KRAS p.G12C Mutant Advanced Solid Tumors 1 Hematologic Neoplasms 1

Interventions

pembrolizumab 2 erdafitinib 2 Gemcitabine 2 Cisplatin 2 Carboplatin 2 vinflunine 1 enfortumab vedotin 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02365597 2026-03-19

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Janssen Research & Development, LLC

Phase 2 Active not recruiting

239 enrolled 32 charts 1 FDA

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡